DESCRIPTION :
It is more potent alpha blocker .this compound belongs to the class of organic compound known as ergopeptines.these are ergoline derivative that contain a tripeptide .
PHARMACODYNAMICS :
It may increase cerebral metabolism and blood flow .The role of this medication in the therapy of dementia is controversial .A recent controlled study in patient with Alzheimer disease found that there was no advantage to use of ergoloid mesylates compared to placebo,further study is needed to determine the risk -benifit profile of it in the treatment of dementia.
MECHANISM OF ACTION :
It act centrally ,decreasing vascular tone & slowing the heart rate & act peripherally to block alpha receptor . One another possible mechanism is the effect of it on neuronal cell metabolism .Resulting in improved oxygen uptake and cerebral metabolism ,thereby normalising depressed neuro-transmitter level .
PHARMACOKINETIC PROPERTY :
Absorption : Absorbed from GIT .Eliminated by 1st pass metabolism .
Protein binding :98-99%
Metabolism :Hepatic
Halflife : 3.5 hr
ADVERSE EFFECT:
Dyspnea
Hypotention
rapid weak pulse
Delirium
Nausea ,vomiting
bradycardia
DRUG -DRUG INTERACTION :
Acepromazine + Dihydroergotoxin =Risk of adverse effect can be increased .
Acetophenazine + Dihydroergotoxin = risk of adverse effect can be increased .
Apripitant + Dihydroergotoxin = serum concentration of ergotoxin can be increased. Boceprevir + Dihydroergotoxin = Serum concentration of ergotoxin may be increased.
THERAPEUTIC USES :
Pheochromocytoma
Hypertention
benign hypertrophy of prostat
congestive heart failure
Pheripheral vascular diseases
No comments:
Post a Comment